A28 Therapeutics and GATC Health Announce Comprehensive AI-Powered Analysis, Predicting Efficacy, Safety, and Potential Off-Target Effects of A28’s AT-101 Cancer Drug Candidate

The analysis provides detailed insights to optimize clinical trial strategy, accelerate development, and de-risk decision-making.

SAN FRANCISCO, CA, USA – January 13, 2025 – A28 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel platform technology for the treatment of multiple cancer types, today announced during the J.P. Morgan Healthcare Conference the completion of a comprehensive activity analysis for its AT-101 cancer drug candidate. This AI analysis by GATC Health Corp, a leader in AI-driven drug discovery, not only validates the potential of AT-101 but also provides A28 Therapeutics with a powerful tool to optimize its clinical trial strategy. By accurately assessing efficacy, safety, and potential off-target effects, the analysis provides actionable insights for reducing development risks, accelerating timelines, and lowering costs, paving the way for a more efficient path to clinical success.

“GATC has set the standard in leveraging advanced AI to objectively analyze drug compounds to provide valuable insight into key endpoints, like mechanisms of action and toxicity, while exposing non-obvious areas of risk,” explained Dr. Stanley Lewis, CEO of A28. “As an advisory board member since 2022, I have had direct access to the GATC team and understanding of the powerful toolset GATC uses to greatly de-risk research, development, and financial decisions. This analysis provides an objective assessment of how our AT-101 drug candidate will perform in our next clinical trial.”

GATC’s Multiomics Advanced Technology™ (MAT) AI platform performed in-silico experiments to determine the safety, efficacy, and side-effect profile for A28’s asset. Specifically, the MAT platform generated predictions for:

• Primary pharmacokinetics.

• Bioaccumulation.

• Toxicology.

• ADME considerations.

• Adverse event analysis.

• Side effects.

• Endpoint matching.

• Efficacy ratios.

• Mechanisms of action.

• Immune response.

“GATC Health’s work with A28 demonstrates our ability to quickly provide deep insights and value into clinical-stage drug candidates utilizing the same technologies we employ for therapeutic discovery and early-stage development that can save years and tens of millions of dollars compared to traditional methods,” noted Jayson Uffens, co-founder and CTO. “This collaboration showcases our value to empower leaders and researchers in biotech to accelerate their pre-clinical development and de-risk their clinical and fundraising efforts.”

A28 Therapeutics, Inc.

A28 Therapeutics is a clinical-stage biotechnology company developing first-in-class targeted oncolytic peptides (TOPs) for the treatment of cancer. A28’s lead candidate, AT-101, is currently being developed to treat hepatocellular carcinoma (HCC), leveraging its unique biodistribution that results in prolonged exposure in the liver. The immunologically favorable mechanism of tumor elimination provides for synergy with existing oncology medications, including immune checkpoint inhibitors. To date, AT-101 has been tested in more than 75 patients, where it demonstrated tolerability and remarkable anti-cancer activity. The A28 TOPs platform has produced a pipeline of products targeting multiple cancer types and cell receptors. For more information, please visit www.a28therapeutics.com.

About GATC Health

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.